Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of The National Comprehensive Cancer Network

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2013.0084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

  2015cited by this paper
• Clinical next‐generation sequencing in patients with non–small cell lung cancer

  2015cited by this paper
• ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Germline EGFR T790M mutation found in multiple members of a familial cohort.

  2014cited by this paper
• American Cancer Society Lung Cancer Screening Guidelines

  2014cited by this paper
• Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria

  2014cited by this paper
• Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

  2014cited by this paper
• Recent clinical advances in lung cancer management.

  2014cited by this paper
• Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

  2014cited by this paper
• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

  2014cited by this paper
• 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

  2014cited by this paper
• Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance

  2014cited by this paper
• Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

  2014cited by this paper
• Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

  2014cited by this paper
• KRAS mutation: should we test for it, and does it matter?

  2013cited by this paper
• Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

  2013cited by this paper
• Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

  2013cited by this paper
• Targeted therapy for non-small-cell lung cancer: past, present and future

  2013cited by this paper
• 21st-century hazards of smoking and benefits of cessation in the United States.

  2013cited by this paper
• Molecular Profiling of Lung Cancer

  2013cited by this paper
• Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial.

  2013cited by this paper
• EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

  2013cited by this paper
• Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

  2013cited by this paper
• Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

  2013cited by this paper
• Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

  2013cited by this paper
• Management of non-small-cell lung cancer: recent developments.

  2013cited by this paper
• Identification of driver mutations in lung cancer: first step in personalized cancer

  2013cited by this paper
• Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• 50-year trends in smoking-related mortality in the United States.

  2013cited by this paper
• The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

  2012cited by this paper
• Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

  2012cited by this paper
• Strategies to help a smoker who is struggling to quit.

  2012cited by this paper
• Benefits and harms of CT screening for lung cancer: a systematic review.

  2012cited by this paper
• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

  2012cited by this paper
• The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.

  2012cited by this paper
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update

  2012cited by this paper
• Lung cancer epidemiology, risk factors, and prevention.

  2012cited by this paper
• Overview and Strategic Management of Subsolid Pulmonary Nodules

  2012cited by this paper
• Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

  2012cited by this paper
• Ten years of progress in non-small cell lung cancer.

  2012cited by this paper
• Diagnosis of Lung Nodules With Peripheral/Radial Endobronchial Ultrasound-guided Transbronchial Biopsy

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Electromagnetic navigation bronchoscopy: A descriptive analysis.

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

  2012cited by this paper
• The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

  2012cited by this paper
• EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

  2012cited by this paper
• Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

  2011cited by this paper
• Lung cancer: epidemiology, etiology, and prevention.

  2011cited by this paper
• Preventing lung cancer by treating tobacco dependence.

  2011cited by this paper
• Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

  2011cited by this paper
• Summary of the British Thoracic Society Guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans.

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Clinical practice. Treating smokers in the health care setting.

  2011cited by this paper
• The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence

  2011cited by this paper
• Crizotinib and testing for ALK.

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer.

  2011cited by this paper
• A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

  2010cited by this paper
• EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

  2010cited by this paper
• Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

  2010cited by this paper
• Mediastinoscopy in patients with lung cancer and negative endobronchial ultrasound guided needle aspiration.

  2010cited by this paper
• Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.

  2010cited by this paper
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• Multicenter Experience With Electromagnetic Navigation Bronchoscopy for the Diagnosis of Pulmonary Nodules

  2010cited by this paper
• EGFR testing in lung cancer is ready for prime time.

  2009cited by this paper
• EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes—an International Multi-Centre Experience

  2009cited by this paper
• A review of human carcinogens--Part F: chemical agents and related occupations.

  2009cited by this paper
• Endobronchial ultrasonography-guided transbronchial needle aspiration increases the diagnostic yield of peripheral pulmonary lesions: a randomized trial.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.

  2009cited by this paper
• A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish.

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• A review of human carcinogens--Part C: metals, arsenic, dusts, and fibres.

  2009cited by this paper
• Role of endobronchial ultrasound-guided transbronchial needle aspiration in the management of lung cancer

  2008cited by this paper
• Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

  2008cited by this paper
• EGFR Assays in Lung Cancer

  2008cited by this paper
• Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

  2007cited by this paper
• Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

  2007cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

  2006cited by this paper

• Paroxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation

  2026cites this paper
• Macrophage‐Mediated Cellular Communication Networks in Lung Squamous Cell Carcinoma and Adenocarcinoma Revealed by Single‐Cell Sequencing

  2026cites this paper
• EGFR Inhibitors Across Generations: Progress, Challenges, and Future Directions

  2025cites this paper
• Novel inhibitors of oncogenic Wnt/TCF-4/β-catenin signaling pathway: Design, synthesis, molecular docking studies and apoptosis inducing activity of pyrimidothiazino-, dihydropyrimidotriazepino- and 1,3,4-thiadiazolopyrimido-indole hybrids.

  2025cites this paper
• Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review

  2025cites this paper
• The association between Chlamydia pneumoniae infection and prognosis in lung cancer patients: a prospective study

  2025cites this paper
• Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution

  2025cites this paper
• Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota.

  2025cites this paper
• Eugenol as a game-changer: overcoming osimertinib resistance in non-small cell lung cancer by inhibiting glycolysis via the tripartite motif containing 59/extracellular signal-regulated kinase pathway.

  2025cites this paper
• Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors

  2025cites this paper
• Real-time margin assessment for video-assisted thoracic surgery: A pilot clinical trial

  2025cites this paper
• From Diagnosis to Survivorship: The Role of Social Determinants in Cancer Care

  2025cites this paper
• Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

  2025cites this paper
• THY1 is a prognostic-related biomarker via mediating immune infiltration in lung squamous cell carcinoma (LUSC)

  2024cites this paper
• Asiatic acid induces lung cancer toxicity by triggering SRC-mediated ferroptosis.

  2024cites this paper
• Bridging the nano-Frontier: revolutionizing lung cancer diagnosis and therapy with nanoparticles

  2024cites this paper
• Urolithin A promotes the degradation of TMSB10 to deformation F-actin in non-small-cell lung cancer.

  2024cites this paper
• Diosmin reduces the stability of Snail and Cyclin D1 by targeting FAK to inhibit NSCLC progression.

  2024cites this paper
• CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer

  2024cites this paper
• Integrative analysis of aging-related genes reveals CEBPA as a novel therapeutic target in non-small cell lung cancer

  2024cites this paper
• Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

  2024cites this paper
• MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non‐small cell lung cancer

  2024cites this paper
• Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes

  2024cites this paper
• Endobronchial ultrasound-guided transbronchial needle injection of cisplatin results in dynamic changes in the tumor immune microenvironment.

  2023cites this paper
• Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy.

  2023cites this paper
• X-ray-downregulated nucleophosmin induces abnormal polarization by anchoring to G-actin.

  2023cites this paper
• Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report

  2023cites this paper
• Integrative analysis of GWAS and transcriptomics data reveal key genes for non-small lung cancer

  2023cites this paper
• Microbiota Diversity in Non-Small Cell Lung Cancer Gut and Mouth Cavity Microbiota Diversity in Non-Small Cell Lung Cancer Patients

  2023cites this paper
• Construction of an EMT-related lncRNA prognostic signature for lung adenocarcinoma and functional verification of its hub gene LINC01615

  2023cites this paper
• Whole-tumor histogram analysis of multi-parametric MRI for differentiating brain metastases histological subtypes in lung cancers: relationship with the Ki-67 proliferation index

  2023cites this paper
• Overview of Lung Cancer

  2023cites this paper
• Tumor-infiltrating platelets promote the growth of lung adenocarcinoma

  2023cites this paper
• Radiomics under 2D regions, 3D regions, and peritumoral regions reveal tumor heterogeneity in non-small cell lung cancer: a multicenter study

  2023cites this paper
• ERBB2 VARIANTS DISTRIBUTION IN NON-SMALL CELL LUNG CANCER: AN ITALIAN REAL-WORLD EXPERIENCE

  2023influential citation
• Mandibular metastasis of pulmonary adenocarcinoma: How unexpected could it be?

  2023cites this paper
• ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma

  2023cites this paper
• Long non-coding RNA TCL6 induced by SCRT1 promotes proliferation and metastasis of non-small cell lung cancer through PDK1/AKT signaling.

  2023cites this paper
• M2 macrophage exosomal LINC01001 promotes non-small cell lung cancer development by affecting METTL3 and glycolysis pathway

  2023cites this paper
• Establishment and Characterization of Patient-Derived Xenograft Model of Non-Small-Cell Lung Cancer Derived from Malignant Pleural Effusions

  2023cites this paper
• Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples

  2023cites this paper
• Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis

  2023cites this paper
• Construction of an individualized brain metabolic network in patients with advanced non-small cell lung cancer by the Kullback-Leibler divergence-based similarity method: A study based on 18F-fluorodeoxyglucose positron emission tomography

  2023cites this paper
• Effect of the Knockout of FGL1 by CRISPR on the GefitinibSensitivity of PC9/GR Cells

  2023influential citation
• Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer

  2022cites this paper
• IL-17A Promotes the Migration, Invasion and the EMT Process of Lung Cancer Accompanied by NLRP3 Activation

  2022cites this paper
• Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation.

  2022cites this paper
• Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer

  2022cites this paper
• Linc00996 is a favorable prognostic factor in LUAD: Results from bioinformatics analysis and experimental validation

  2022cites this paper
• Tumour cell suppression by spiroleucettadine through dual regulation of cell cycle and apoptosis

  2022cites this paper
• The Impact of Air Pollution on Pulmonary Diseases: A Case Study from Brasov County, Romania

  2022cites this paper
• Integrative Analysis of Pyroptosis-Related Prognostic Signature and Immunological Infiltration in Lung Squamous Cell Carcinoma

  2022cites this paper
• A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC

  2022influential citation
• Lung cancer risk in workers occupationally exposed to polycyclic aromatic hydrocarbons with emphasis on the role of DNA repair gene

  2022cites this paper
• Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients

  2022cites this paper
• Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study

  2022cites this paper
• Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer

  2022cites this paper
• Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples

  2022cites this paper
• ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

  2022cites this paper
• Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients With Non-Small Cell Lung Cancer

  2022cites this paper
• LINC01426 Triggers Growth and Metastasis of Lung Adenocarcinoma as a Prognostic Indicator

  2022cites this paper
• Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity

  2022cites this paper
• The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments

  2022cites this paper
• CircPIM3 regulates taxol resistance in non-small cell lung cancer via miR-338-3p/TNFAIP8 axis

  2022cites this paper
• A Comparative Analysis of Video-Assisted Thoracoscopic Surgery and Thoracotomy in Non-Small-Cell Lung Cancer in Terms of Their Oncological Efficacy in Resection: A Systematic Review

  2022cites this paper
• Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells

  2021cites this paper
• Role of delayed phase contrast-enhanced CT in the intra-thoracic staging of non-small cell lung cancer (NSCLC): What does it add?

  2021cites this paper
• Construction of a Prognostic Model in Lung Adenocarcinoma Based on Ferroptosis-Related Genes

  2021cites this paper
• Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer

  2021cites this paper
• A New Lectin from Auricularia auricula Inhibited the Proliferation of Lung Cancer Cells and Improved Pulmonary Flora

  2021cites this paper
• Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia

  2021cites this paper
• Management of Complications During Video-Assisted Thoracic Surgery Lung Resection and Lymph Node Dissection

  2021cites this paper
• Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.

  2021cites this paper
• m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma

  2021cites this paper
• Predictive Radiomic Models for the Chemotherapy Response in Non-Small-Cell Lung Cancer based on Computerized-Tomography Images

  2021cites this paper
• Global evolution of research on pulmonary nodules: a bibliometric analysis.

  2021cites this paper
• Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities

  2021cites this paper
• First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

  2021influential citation
• Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

  2021cites this paper
• LINC00941 Promotes Progression of Non-Small Cell Lung Cancer by Sponging miR-877-3p to Regulate VEGFA Expression

  2021cites this paper
• Erken Evre Küçük Hücreli Dışı Akciğer Kanserlerinin Tedavisinde Robotik Radyocerrahi

  2021cites this paper
• De novo serine biosynthesis from glucose predicts sex-specific response to antifolates in non-small cell lung cancer cell lines

  2021cites this paper
• Identification of NSP3 (SH2D3C) as a Prognostic Biomarker of Tumor Progression and Immune Evasion for Lung Cancer and Evaluation of Organosulfur Compounds from Allium sativum L. as Therapeutic Candidates

  2021cites this paper
• Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer

  2021cites this paper
• 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer.

  2021cites this paper
• Investigation on the Efficiency of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Vinorelbine and Cisplatin Based on Multidimensional Bayesian Network Meta-Analysis

  2021cites this paper
• Identification of seven‐gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi‐omics data analysis

  2021cites this paper
• Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.

  2020cites this paper
• MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1

  2020cites this paper
• Role of Autophagy in Cancer Cell Metabolism

  2020cites this paper
• Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma

  2020cites this paper
• Adjuvant chemotherapy as a risk factor for chronic postoperative pain after video-assisted thoracoscopic surgery: a 10-year single-centre retrospective study.

  2020cites this paper
• Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand

  2020cites this paper
• Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer

  2020cites this paper
• microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner

  2020cites this paper
• miR-124-3p Regulates FGF2–EGFR Pathway to Overcome Pemetrexed Resistance in Lung Adenocarcinoma Cells by Targeting MGAT5

  2020cites this paper
• Image guided thermal ablation in lung cancer treatment

  2020cites this paper
• An advanced c-MET-amplified NSCLC patient that was treated with crizotinib

  2020cites this paper
• Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5

  2020cites this paper
• Single‐nucleotide polymorphism rs4142441 and MYC co‐modulated long non‐coding RNA OSER1‐AS1 suppresses non‐small cell lung cancer by sequestering ELAVL1

  2020cites this paper